FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Papier
Retour à la bibliothèque de recherche
PubMedMeta-AnalysisSujets humains

Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.

Tewari Jay, Qidwai Khalid Ahmad, Tewari Ajoy, Kaur Savneet, Tewari Vineeta, Maheshwari Anuj
Expert review of clinical pharmacology2025DOI: 10.1080/17512433.2025.2450254
retatrutidetriple hormone receptor agonist

Note de qualité

8/10

Citations

0

Sujets

Humain

Analyse Peptide Contacts

Study Design

By pooling data across multiple studies, this meta-analysis achieves statistical power that no individual trial could match alone. The combined sample size strengthens confidence in the effect estimates reported.

Our Assessment

Quality Assessment: 8/10 — This paper meets our highest quality thresholds. The methodology is well-designed, the statistical analysis is appropriate, and the conclusions are well-supported by the data presented. This is a reference-grade study for the peptides it covers.

Findings in Context

These findings advance our understanding of retatrutide, triple hormone receptor agonist in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for retatrutide, triple hormone receptor agonist. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Trouvailles clés

Retatrutide demonstrated a dose-dependent efficacy in reducing obesity-related outcomes compared to placebo, with the highest dose (12 mg) showing maximum reductions. The safety profile was comparable to that of the control group.

Limites

The study relies on data from only four randomized controlled trials, which may limit the generalizability and robustness of the findings. Further large-scale clinical trials are needed for more definitive conclusions.

Comment interpréter cette recherche

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Analyse Peptide Contacts

Highlighting the promising preliminary results of retatrutide for obesity management through a systematic review and meta-analysis, emphasizing the need for further research.

retatrutidetriple hormone receptor agonist

Novel Triple Hormone Receptor Agonist Shows Promise in Obesity Management

Published: May 16, 2026 | Source: Expert review of clinical pharmacology (2025) | Category: retatrutide, triple hormone receptor agonist

Overview

A recent systematic review and meta-analysis published in Expert Review of Clinical Pharmacology highlights the potential of retatrutide, a novel triple hormone receptor agonist, for managing obesity. The study synthesizes data from four randomized controlled trials (RCTs) and suggests that retatrutide is more effective than placebo in reducing obesity-related outcomes, with minimal safety concerns.

Study Background

Obesity management has long been a challenge due to the complexity of metabolic pathways involved. Retatrutide, by targeting multiple hormone receptors simultaneously, offers a promising approach to weight loss. This meta-analysis aimed to consolidate existing evidence on retatrutide's efficacy and safety profile, providing insights for both researchers and clinicians.

What the Research Found

The systematic review included four RCTs that compared retatrutide with placebo in managing obesity. The analysis revealed a dose-dependent relationship between retatrutide dosage and weight loss outcomes. Specifically, participants receiving 12 mg of retatrutide experienced the most significant reductions in body mass index (BMI) and waist circumference compared to those on lower doses or placebo.

In terms of safety, no major adverse events were reported with retatrutide use, indicating a comparable safety profile to the control group. This suggests that retatrutide may be well-tolerated by patients undergoing obesity management treatments.

What This Means for Peptide Users

While these findings are encouraging, it is important to note that retatrutide is still in its early stages of clinical development. The current data supports further investigation into this peptide's potential benefits and long-term safety profile. For individuals considering the use of peptides like retatrutide, consulting with a healthcare provider remains crucial.

Limitations and Caveats

The study’s reliance on only four RCTs limits the generalizability of its findings. Additionally, the lack of longer-term data means that potential side effects or benefits over extended periods remain unknown. These limitations underscore the need for larger, more comprehensive clinical trials to validate retatrutide's efficacy and safety.

How This Compares to Previous Research

Previous studies on single hormone receptor agonists have shown mixed results in terms of both efficacy and safety. Retatrutide’s multi-receptor approach appears to offer a promising alternative by potentially enhancing therapeutic effects while maintaining a favorable safety profile. However, direct comparisons with other peptides are limited due to the novelty of retatrutide.

Our Analysis

PeptideVault's analysis suggests that this meta-analysis provides valuable preliminary evidence supporting retatrutide’s potential as an obesity management tool. The study adheres to rigorous methodologies and presents clear findings regarding efficacy and safety. Nonetheless, the need for further research is evident to address current limitations and provide a more robust understanding of retatrutide's long-term effects.

Key Takeaways

  • Retatrutide shows promise in reducing obesity-related outcomes compared to placebo.
  • A dose-dependent relationship exists between retatrutide dosage and efficacy.
  • Current safety data suggests that retatrutide is well-tolerated, but more research is needed for comprehensive understanding.
  • Consultation with healthcare providers remains essential for individuals considering peptide therapy.

Original Source

Citation: Tewari Jay, Qidwai Khalid Ahmad, Tewari Ajoy et al. (2025). Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.. Expert review of clinical pharmacology. DOI: 10.1080/17512433.2025.2450254

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Note de l'éditeur

Cette analyse a été rédigée par l'équipe de recherche de Peptide Contacts pour rendre les découvertes complexes accessibles à la communauté des peptides. Nous encourageons les lecteurs à vérifier le papier source pour une méthodologie et des données complètes. Pour plus d'informations sur retatrutide, explorez nos guides de recherche.

Citation

Tewari Jay, Qidwai Khalid Ahmad, Tewari Ajoy et al.. (2025). Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.. Expert review of clinical pharmacology. https://doi.org/10.1080/17512433.2025.2450254

Voir le texte intégral sur PubMed

Papiers connexes

Explorer davantage

Ce contenu est dérivé d'une recherche peer-reviewed pour des fins éducatives uniquement. Il ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant d'utiliser tout traitement basé sur les peptides.